Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Price:
8.77
USD
1.98%
Market Closed
Market Cap:
847.4m
USD
Balance Sheet
Balance Sheet Decomposition
Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals PLC
| Current Assets | 134.2m |
| Cash & Short-Term Investments | 73.8m |
| Receivables | 34.1m |
| Other Current Assets | 26.3m |
| Non-Current Assets | 30m |
| PP&E | 2.2m |
| Intangibles | 16.8m |
| Other Non-Current Assets | 11m |
Balance Sheet
Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals PLC
Currency: USD
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
65
|
39
|
17
|
9
|
10
|
72
|
51
|
74
|
31
|
51
|
|
| Cash Equivalents |
65
|
39
|
17
|
9
|
10
|
72
|
51
|
74
|
31
|
51
|
|
| Short-Term Investments |
80
|
115
|
78
|
94
|
54
|
151
|
107
|
23
|
74
|
22
|
|
| Total Receivables |
14
|
19
|
17
|
14
|
12
|
39
|
32
|
3
|
13
|
34
|
|
| Accounts Receivables |
7
|
18
|
15
|
12
|
9
|
17
|
0
|
0
|
12
|
34
|
|
| Other Receivables |
7
|
1
|
2
|
3
|
4
|
22
|
32
|
2
|
1
|
0
|
|
| Inventory |
4
|
3
|
6
|
5
|
4
|
0
|
0
|
0
|
10
|
20
|
|
| Other Current Assets |
3
|
5
|
7
|
2
|
2
|
1
|
3
|
2
|
5
|
6
|
|
| Total Current Assets |
166
|
181
|
124
|
125
|
82
|
263
|
192
|
101
|
134
|
134
|
|
| PP&E Net |
3
|
3
|
3
|
2
|
4
|
3
|
3
|
3
|
3
|
2
|
|
| PP&E Gross |
3
|
3
|
3
|
2
|
4
|
3
|
3
|
3
|
3
|
2
|
|
| Accumulated Depreciation |
15
|
12
|
15
|
13
|
1
|
1
|
0
|
1
|
1
|
1
|
|
| Intangible Assets |
16
|
23
|
92
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
18
|
18
|
18
|
18
|
18
|
17
|
17
|
17
|
17
|
17
|
|
| Note Receivable |
0
|
2
|
5
|
7
|
6
|
3
|
1
|
1
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
3
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
12
|
18
|
7
|
35
|
38
|
25
|
34
|
11
|
10
|
11
|
|
| Other Assets |
18
|
18
|
18
|
18
|
18
|
17
|
17
|
17
|
17
|
17
|
|
| Total Assets |
215
N/A
|
245
+14%
|
253
+3%
|
190
-25%
|
151
-20%
|
312
+106%
|
247
-21%
|
133
-46%
|
165
+24%
|
164
0%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
5
|
7
|
7
|
4
|
6
|
3
|
8
|
8
|
11
|
7
|
|
| Accrued Liabilities |
4
|
9
|
40
|
15
|
14
|
6
|
13
|
10
|
25
|
41
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
38
|
0
|
0
|
|
| Other Current Liabilities |
36
|
46
|
39
|
20
|
16
|
6
|
1
|
0
|
0
|
0
|
|
| Total Current Liabilities |
45
|
62
|
87
|
38
|
36
|
15
|
21
|
56
|
37
|
49
|
|
| Long-Term Debt |
1
|
1
|
0
|
116
|
122
|
128
|
142
|
92
|
0
|
0
|
|
| Other Liabilities |
100
|
140
|
81
|
33
|
23
|
6
|
6
|
7
|
40
|
42
|
|
| Total Liabilities |
146
N/A
|
203
+39%
|
168
-18%
|
188
+12%
|
181
-4%
|
149
-17%
|
169
+13%
|
154
-9%
|
77
-50%
|
90
+17%
|
|
| Equity | |||||||||||
| Common Stock |
6
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
279
|
320
|
263
|
358
|
391
|
384
|
448
|
585
|
745
|
794
|
|
| Additional Paid In Capital |
364
|
385
|
393
|
434
|
434
|
567
|
549
|
590
|
855
|
892
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
23
|
24
|
1
|
2
|
0
|
2
|
1
|
0
|
|
| Treasury Stock |
0
|
0
|
22
|
50
|
50
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
23
|
24
|
0
|
0
|
24
|
23
|
24
|
24
|
24
|
25
|
|
| Total Equity |
69
N/A
|
42
-39%
|
86
+103%
|
3
-97%
|
29
N/A
|
162
N/A
|
78
-52%
|
21
N/A
|
88
N/A
|
74
-16%
|
|
| Total Liabilities & Equity |
215
N/A
|
245
+14%
|
253
+3%
|
190
-25%
|
151
-20%
|
312
+106%
|
247
-21%
|
133
-46%
|
165
+24%
|
164
0%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
41
|
41
|
39
|
37
|
38
|
58
|
59
|
63
|
90
|
97
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
